Medicare Benefits Schedule - Item 73304

Search Results for Item 73304

View Associated Notes

Category 6 - PATHOLOGY SERVICES

73304

73304 - Additional Information

Item Start Date:
01-Apr-2022
Description Updated:
01-Apr-2022
Schedule Fee Updated:
01-Apr-2022

Group
P7 - Genetics

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme.

Applicable once per lifetime

Fee: $1,000.00 Benefit: 75% = $750.00 85% = $912.10

(See para PN.0.27 of explanatory notes to this Category)


Associated Notes

Category 6 - PATHOLOGY SERVICES

PN.0.27

Germline BRCA gene mutation tests (Items 73295, 73296, 73304 and 73333)

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

Related Items: 73295 73296 73304 73333


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change